46.09
0.83 (1.83%)
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Bearish |
| Biotechnology (Global) | Mixed | Bearish | |
| Stock | Dyne Therapeutics, Inc. | Bullish | Bullish |
Stockmoo Score
|
Dyne Therapeutics Inc is a biotechnology company focused on providing therapeutics for patients with genetically driven diseases. The company overcomes the limitations of muscle tissue delivery and modern oligonucleotide therapeutics for muscle diseases. The company is developing therapies for muscle disorders like Myotonic dystrophy, Duchenne muscular dystrophy, and Facioscapulohumeral muscular dystrophy. The company's product candidates are DYNE-101 and DYNE-251, both are in the ongoing phase 1/2 clinical trial. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Core |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Fcpm Iii Services B.V. | 30 Jun 2024 | 7,845,364 |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 66.00 (Stifel, 43.20%) | Buy |
| Median | 53.00 (14.99%) | |
| Low | 43.00 (JP Morgan, -6.70%) | Buy |
| Average | 53.43 (15.93%) | |
| Total | 7 Buy | |
| Avg. Price @ Call | 40.22 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| HC Wainwright & Co. | 04 Sep 2024 | 55.00 (19.33%) | Buy | 33.76 |
| 13 Aug 2024 | 55.00 (19.33%) | Buy | 43.64 | |
| Oppenheimer | 03 Sep 2024 | 55.00 (19.33%) | Buy | 31.94 |
| Stifel | 16 Aug 2024 | 66.00 (43.20%) | Buy | 45.39 |
| Guggenheim | 15 Aug 2024 | 50.00 (8.48%) | Buy | 45.74 |
| Morgan Stanley | 14 Aug 2024 | 52.00 (12.82%) | Buy | 43.88 |
| Piper Sandler | 13 Aug 2024 | 53.00 (14.99%) | Buy | 43.64 |
| JP Morgan | 09 Jul 2024 | 43.00 (-6.70%) | Buy | 37.21 |
| Name | Avg. Buy ($) | Avg. Sell ($) | Net Quantity | Net Value ($) |
|---|---|---|---|---|
| COX JOHN | 33.76 | - | 32,000 | 1,080,320 |
| FRIEDL-NADERER JOHANNA | 31.94 | - | 58,400 | 1,865,296 |
| KERR DOUGLAS | 31.94 | - | 47,500 | 1,517,150 |
| KERSTEN DIRK | - | 45.05 | -320,461 | -14,396,126 |
| Aggregate Net Quantity | -182,561 | |||
| Aggregate Net Value ($) | -9,933,360 | |||
| Aggregate Avg. Buy ($) | 32.55 | |||
| Aggregate Avg. Sell ($) | 45.05 | |||
| Insider Range ($) | ||||
| Name | Holder | Date | Type | Quantity | Price | Value ($) |
|---|---|---|---|---|---|---|
| COX JOHN | Officer | 04 Sep 2024 | Buy (+) | 32,000 | 33.76 | 1,080,320 |
| FRIEDL-NADERER JOHANNA | Officer | 03 Sep 2024 | Acquired (+) | 58,400 | 31.94 | 1,865,296 |
| KERR DOUGLAS | Officer | 03 Sep 2024 | Acquired (+) | 47,500 | 31.94 | 1,517,150 |
| KERSTEN DIRK | Director | 30 Aug 2024 | Automatic sell (-) | 31,300 | 46.09 | 1,442,617 |
| KERSTEN DIRK | Director | 29 Aug 2024 | Automatic sell (-) | 56,408 | 45.26 | 2,553,026 |
| KERSTEN DIRK | Director | 28 Aug 2024 | Automatic sell (-) | 77,853 | 45.01 | 3,504,164 |
| KERSTEN DIRK | Director | 27 Aug 2024 | Automatic sell (-) | 65,403 | 44.03 | 2,879,694 |
| KERSTEN DIRK | Director | 26 Aug 2024 | Automatic sell (-) | 89,497 | 44.88 | 4,016,625 |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2024 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |